guest ::
| Home > Publications Database > Plasma biomarkers of amyloid, tau & neuroinflammation in Alzheimer's disease and corticobasal syndrome. |
| Home > Publications Database > Plasma biomarkers of amyloid, tau & neuroinflammation in Alzheimer's disease and corticobasal syndrome. |
| Journal Article | DZNE-2025-01313 |
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
2025
Springer
Heidelberg
This record in other databases: 
Please use a persistent id in citations: doi:10.1007/s00406-025-02013-z
Abstract: Blood-based biomarkers (BBBMs) could significantly facilitate the diagnosis of Alzheimer's disease (AD) and non-AD dementia by providing less invasive alternatives to cerebrospinal fluid (CSF) and positron emission tomography (PET) imaging.This study investigated how well the BBBMs-amyloid-β (Aβ) 1-42/1-40 ratio, phosphorylated tau181 (pTau181), apolipoprotein E4 (ApoE4), glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL)-reflect thorough clinical work-up validated by PET and CSF biomarkers in participants with AD (n = 27), Aβ-negative CBS (n = 26), and agematched healthy controls (HC) (n = 17).Factor and correlation explored biomarker associations. Bayesian regression, backward selection regression, and ROC curve analysis were applied to identify optimal biomarker combinations and diagnostic cut-offs.In AD cases, pTau181 and ApoE4 levels were elevated, and the Aβ1-42/1-40 ratio was reduced. ROC analysis showed high accuracy for pTau181, ApoE4 and Aβ1-42/1-40 in discriminating AD from HC, with a combination significantly improving performance. However, limited fold change, and high variability reduced the diagnostic applicability of Aβ1-42/1-40 ratio. Elevated NfL levels were the most reliable biomarker for CBS-Aβ(-) cases. GFAP showed limited discriminatory power due to overlapping levels, suggesting that it may not serve as a disease-specific biomarker but may be indicative of general neurodegeneration.This study highlights the diagnostic utility of pTau181, ApoE4 and the Aβ1-42/1-40 ratio for AD and NfL in the CBS-Aβ(-) cases and emphasizes the added value of combined biomarker models for group differentiation. Prospective studies will help validate these findings and refine clinical thresholds.
Keyword(s): Humans (MeSH) ; Alzheimer Disease: blood (MeSH) ; Alzheimer Disease: diagnosis (MeSH) ; tau Proteins: blood (MeSH) ; Female (MeSH) ; Amyloid beta-Peptides: blood (MeSH) ; Biomarkers: blood (MeSH) ; Aged (MeSH) ; Male (MeSH) ; Peptide Fragments: blood (MeSH) ; Glial Fibrillary Acidic Protein: blood (MeSH) ; Middle Aged (MeSH) ; Neurofilament Proteins: blood (MeSH) ; Neuroinflammatory Diseases: blood (MeSH) ; Apolipoprotein E4: blood (MeSH) ; Aged, 80 and over (MeSH) ; Corticobasal Degeneration: blood (MeSH) ; Corticobasal Degeneration: diagnosis (MeSH) ; Positron-Emission Tomography (MeSH) ; Apolipoprotein E (ApoE4) ; Beta-amyloid 1-40 (Aβ1-40) ; Beta-amyloid 1-42 (Aβ1-42) ; Glial fibrillary acidic protein (GFAP) ; Neurofilament light chain (NfL) ; Non-Alzheimer's disease dementia; beta ; Phosphorylated tau (pTau) ; tau Proteins ; Amyloid beta-Peptides ; Biomarkers ; Peptide Fragments ; Glial Fibrillary Acidic Protein ; Neurofilament Proteins ; Apolipoprotein E4 ; amyloid beta-protein (1-42) ; neurofilament protein L ; GFAP protein, human ; amyloid beta-protein (1-40) ; MAPT protein, human
; 
; 
; SCOPUS
PDF
PDF (PDFA)